A time-honored tradition in business media is searching through companies’ annual reports to see just how much they pay their treasured CEOs. As of this year, thanks to a provision in the Dodd-Frank law, it’s also possible to learn the median pay among employees at these companies.
In biopharma, that pay is pretty ample.
Using data from MyLogIQ, which collects data from filings from the Securities and Exchange Commission, we charted the median salaries for 32 biopharma companies, ranging from the tiny Geron to the multinational Johnson & Johnson. The result: The drug business pays better than any other industry, according to MyLogIQ.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
